Fred Aslan - 18 Jul 2024 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Role
President and CEO, Director
Signature
/s/ Neha Krishnamohan, Attorney-in-Fact
Issuer symbol
ARTV
Transactions as of
18 Jul 2024
Net transactions value
$0
Form type
4
Filing time
22 Jul 2024, 20:18:50 UTC
Next filing
07 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARTV Common Stock Award $0 +228,905 $0.000000 228,905 22 Jul 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARTV Employee Stock Option (Right to Buy) Award $0 +343,811 $0.000000 343,811 18 Jul 2024 Common Stock 343,811 $12.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
F2 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.